Research & Treatments

ResearchTreatments

Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation

*October 2021* Purpose: This study aimed to explore the clinical value of SBRT for primary lung lesions of EGFR-mutant NSCLC patients with non-oligometastatic disease during first-line EGFR-TKI treatment. Methods: We identified patients with stage IV EGFR-mutant non-oligometastatic NSCLC who were suitable to receive SBRT for the primary tumors after EGFR-TKI treatment. All…
laurabbook@gmail.com
November 12, 2021
ResearchTreatments

Sintilimab Meets Primary End Point in ORIENT-31 Trial for EGFR+ Non-Squamous NSCLC

*October 2021* Sintilimab with or without a bevacizumab biosimilar injection, combined with chemotherapy yielded promising findings in a population of patients with EGFR-mutant nonsquamous non–small cell lung cancer who have previously been treated with an EGFR tyrosine kinase inhibitor. Sintilimab (Tyvyt) has yielded a promising improvement to progression-free survival (PFS)…
laurabbook@gmail.com
November 12, 2021
ResearchTreatments

Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure

*July 2021* Highlights Pemetrexed-carbo plus bevacizumab and atezolizumab was effective in EGFR mutated lung cancer. Median PFS of 9.4 months, 1 year OS 72.5% in this heavily pretreated population were remarkable. Having similar efficacy, this regimen gave less toxicity compared with IMPower150 regimen. QoL was well preserved in patients which used pemetrexed…
laurabbook@gmail.com
November 12, 2021
ResearchTreatments

New Mechanisms Under Study to Overcome Osimertinib Resistance in EGFR+ NSCLC

*October 2021* Several small molecule EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutated non–small cell lung cancer (NSCLC). However, progression after TKI therapy—including with the third-generation TKI osimertinib (Tagrisso)—is inevitable. Results of several studies targeting new treatment strategies were reported at the recent International Association for…
laurabbook@gmail.com
November 12, 2021